Chief Justice of Hungary

Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Retrieved on: 
Thursday, January 18, 2024

Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.
  • The tumor-naïve plasma based test is available for research use only to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage CRC after surgery.
  • xM is a liquid biopsy approach to MRD assessment, where no baseline tumor tissue is required.
  • “Colorectal cancer is the second leading cause of cancer-related deaths worldwide,1 and surgical intervention alone may not be curative for all patients.

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

Retrieved on: 
Thursday, November 16, 2023

“An increasing number of our companion diagnostic pharmaceutical partners are requesting complementary whole exome and whole transcriptome testing on their patients’ tumors,” said Paul Diaz, President and CEO, Myriad Genetics.

Key Points: 
  • “An increasing number of our companion diagnostic pharmaceutical partners are requesting complementary whole exome and whole transcriptome testing on their patients’ tumors,” said Paul Diaz, President and CEO, Myriad Genetics.
  • It provides high-quality exome/transcriptome assays for cancer FFPE samples.
  • “A key pillar of our strategy is to expand our reach through commercial partnerships and this new collaboration with Myriad is an exciting milestone of our progress,” said Chris Hall, CEO and President of Personalis.
  • Financial details of the partnership were not disclosed.

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Retrieved on: 
Monday, December 4, 2023

Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff.

Key Points: 
  • Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff.
  • By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually.
  • This action, along with the recently announced Tempus collaboration , is expected to extend the cash position of the company into 2026.
  • “Continuing to optimize our resources, as well as building new relationships, have been goals for us this year as we position Personalis to be a clinical testing leader,” stated Chris Hall, President and CEO of Personalis.

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Retrieved on: 
Tuesday, November 28, 2023

NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity.

Key Points: 
  • NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity.
  • The test was launched by Personalis in October of this year.
  • The two companies will work together exclusively in tumor-informed MRD testing for lung cancer, as well as breast cancer and immunotherapy monitoring after clinical validation of NeXT Personal Dx in those indications.
  • The agreement contemplates testing up to tens of thousands of new patients over the next three years.

Personalis Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights.
  • The conference call can be accessed live by dialing 844-826-3035 for domestic callers or 412-317-5195 for international callers.
  • The live webinar can be accessed at https://investors.personalis.com .
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Retrieved on: 
Thursday, October 26, 2023

(Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer.

Key Points: 
  • (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer.
  • “We’re excited to work with oncologists through this Early Access Program to detect cancer even earlier and increase confidence in clinical decisions.
  • The EAP will enable oncologists to access NeXT Personal Dx for clinical use, with a focus on lung cancer, breast cancer, and immunotherapy response monitoring.
  • Personalis also recently announced data from the groundbreaking TRACERx study investigating the use of NeXT Personal in early-stage lung cancer for MRD and recurrence detection.

Personalis to Announce Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, October 24, 2023

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023.
  • In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Interested parties may access the call by dialing 844-826-3035 for domestic callers or 412-317-5195 for international callers.
  • The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com.

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

Retrieved on: 
Saturday, October 21, 2023

(Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.

Key Points: 
  • (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.
  • Lung cancer is the second most common cancer in the U.S., with an estimated 238,000 new cases and approximately 127,000 deaths forecasted for 2023.
  • For the current analysis, the teams used NeXT Personal to identify and track MRD in over 170 patients from the TRACERx cohort.
  • The study demonstrated that pre-surgical ctDNA levels with NeXT Personal could be used to classify early-stage lung cancer patients into lower- and higher-recurrence risk groups.

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Retrieved on: 
Wednesday, October 18, 2023

(Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance.

Key Points: 
  • (Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance.
  • With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test.
  • She was most recently VP, Regulatory Affairs at GRAIL, and previously held senior positions at Roche Diagnostics and Abbott Vascular.
  • “We are excited to leverage her experience in our space and welcome her on our executive team.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, August 25, 2023

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Personalis is making this announcement as required by Nasdaq rules.
  • All of the inducement stock options were granted on August 15, 2023 and have an exercise price of $1.81 per share, which is equal to the closing price of Personalis’ common stock on the grant date.
  • The foregoing inducement awards are subject to the terms and conditions of Personalis’ 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering each grant.